CA3109184A1 - Treatment of b cell malignancies - Google Patents

Treatment of b cell malignancies Download PDF

Info

Publication number
CA3109184A1
CA3109184A1 CA3109184A CA3109184A CA3109184A1 CA 3109184 A1 CA3109184 A1 CA 3109184A1 CA 3109184 A CA3109184 A CA 3109184A CA 3109184 A CA3109184 A CA 3109184A CA 3109184 A1 CA3109184 A1 CA 3109184A1
Authority
CA
Canada
Prior art keywords
nribrlc
compound
mixture
alkyl
nriac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109184A
Other languages
English (en)
French (fr)
Inventor
Daniel P. Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CA3109184A1 publication Critical patent/CA3109184A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3109184A 2018-08-14 2019-08-13 Treatment of b cell malignancies Pending CA3109184A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US62/718,929 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US62/775,797 2018-12-05
US201962836511P 2019-04-19 2019-04-19
US62/836,511 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
CA3109184A1 true CA3109184A1 (en) 2020-02-20

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109184A Pending CA3109184A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Country Status (14)

Country Link
US (1) US20210299134A1 (https=)
EP (1) EP3836935A4 (https=)
JP (1) JP2021534115A (https=)
KR (1) KR20210043635A (https=)
CN (1) CN112888441A (https=)
AU (1) AU2019321432A1 (https=)
BR (1) BR112021002760A2 (https=)
CA (1) CA3109184A1 (https=)
IL (1) IL280726A (https=)
MA (1) MA53236A (https=)
MX (1) MX2021001606A (https=)
SG (1) SG11202101450VA (https=)
TW (1) TW202021591A (https=)
WO (1) WO2020036999A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011338530B2 (en) * 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
TWI572599B (zh) * 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
HUE049175T2 (hu) * 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
KR20180042356A (ko) * 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
EP3487878A4 (en) * 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
IL292938A (en) * 2016-09-19 2022-07-01 Mei Pharma Inc Combined treatment
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Also Published As

Publication number Publication date
CN112888441A (zh) 2021-06-01
WO2020036999A1 (en) 2020-02-20
TW202021591A (zh) 2020-06-16
KR20210043635A (ko) 2021-04-21
EP3836935A1 (en) 2021-06-23
MA53236A (fr) 2021-06-23
EP3836935A4 (en) 2022-09-14
IL280726A (en) 2021-03-25
SG11202101450VA (en) 2021-03-30
MX2021001606A (es) 2021-04-19
BR112021002760A2 (pt) 2021-05-11
JP2021534115A (ja) 2021-12-09
AU2019321432A1 (en) 2021-03-25
US20210299134A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US12037346B2 (en) Amino-substituted heteroaryls for treating cancers with EGFR mutations
CN107108637B (zh) 三唑并嘧啶化合物及其用途
CN105899493B (zh) 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JP2021517116A (ja) 併用療法
TW202545942A (zh) Ｃｄｋ抑制劑
US11351176B2 (en) Combination therapy
KR20190058550A (ko) 병용 요법
CA3109184A1 (en) Treatment of b cell malignancies
CA3109377A1 (en) Treatment of relapsed follicular lymphoma
TW202021592A (zh) 組合療法
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
WO2024130344A1 (en) Transient receptor potential vanilloid 6 inhibitors
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors